Rockwell Medical (NASDAQ:RMTI) Issues Quarterly Earnings Results

Rockwell Medical (NASDAQ:RMTI) issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.03), Zacks reports. Rockwell Medical had a negative net margin of 7.98% and a negative return on equity of 15.41%. The business had revenue of $17.34 million during the quarter, compared to analyst estimates of $17.95 million.

Here are the key takeaways from Rockwell Medical’s conference call:

• Rockwell raised 2026 guidance to $70–75M in net sales, projects 18–22% gross margin, expects $1–2M Adjusted EBITDA, positive operating cash flow, and targets positive net income in H2 2026.
• Operational changes — including activation of two automated liquid lines expected to boost output ~50% — should materially lower manufacturing cost per bottle and are estimated to add ~$3M of gross profit (roughly half realizable in 2026).
• Q1 results showed $17.3M in sales (down 8% YoY due to a large customer’s volume decline), gross profit of $2.9M and 17% gross margin (up from 16%); Adjusted EBITDA improved slightly to a negative $0.3M, and cash was $23.9M at quarter end.
• Customer diversification and commercial traction strengthened — ~300 customers covering 1,400+ facilities (including all five leading U.S. dialysis providers), sales in 30+ countries, and recent contract renewals/new wins with improved pricing and product mix.
• Management reiterated long-term targets (by 2029: >$100M sales, gross margin approaching 30%, and annual profitability of $5–10M), but these remain forward‑looking goals subject to execution and risks.

Rockwell Medical Stock Up 2.7%

RMTI opened at $0.64 on Tuesday. The stock’s fifty day simple moving average is $0.81 and its 200 day simple moving average is $0.91. Rockwell Medical has a 1-year low of $0.60 and a 1-year high of $2.10. The stock has a market cap of $25.34 million, a PE ratio of -4.28 and a beta of 1.58. The company has a current ratio of 3.74, a quick ratio of 3.43 and a debt-to-equity ratio of 0.23.

Hedge Funds Weigh In On Rockwell Medical

Several institutional investors and hedge funds have recently modified their holdings of the stock. XTX Topco Ltd raised its position in shares of Rockwell Medical by 286.5% in the fourth quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock valued at $52,000 after purchasing an additional 46,029 shares during the period. Jane Street Group LLC bought a new position in Rockwell Medical in the 4th quarter valued at about $84,000. Geode Capital Management LLC lifted its position in Rockwell Medical by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock worth $304,000 after acquiring an additional 41,668 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in Rockwell Medical by 12.3% during the third quarter. Vanguard Group Inc. now owns 1,354,147 shares of the company’s stock worth $1,625,000 after acquiring an additional 148,737 shares during the last quarter. 23.31% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently commented on RMTI shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Rockwell Medical in a report on Tuesday, April 21st. Wall Street Zen upgraded shares of Rockwell Medical from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Finally, HC Wainwright reiterated a “buy” rating and issued a $2.00 price target on shares of Rockwell Medical in a research note on Friday, May 22nd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $2.00.

Rockwell Medical Company Profile

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.